Cargando…
A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia
Despite the progress made to improve therapeutic outcomes for acute myeloid leukemia (AML), many unmet clinical needs remain to be resolved. Unlike existing anti-AML strategies, here we developed a biomimetic nanocomposite to efficiently eliminate the leukemia cells in the bone marrow and prevent th...
Autores principales: | Kong, Fei, He, Hongliang, Bai, Huiyuan, Yang, Fang, Ma, Ming, Gu, Ning, Zhang, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976099/ https://www.ncbi.nlm.nih.gov/pubmed/35415298 http://dx.doi.org/10.1016/j.bioactmat.2022.03.022 |
Ejemplares similares
-
Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
por: Peled, Amnon, et al.
Publicado: (2013) -
Prognostic significance of CXCR4 expression in acute myeloid leukemia
por: Du, Wen, et al.
Publicado: (2019) -
The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML)
por: Korbecki, Jan, et al.
Publicado: (2023) -
CXCR4 Antagonism to Treat Delayed Fracture Healing
por: Meeson, Richard, et al.
Publicado: (2019) -
Constructing Biopolymer-Inorganic Nanocomposite through a Biomimetic Mineralization Process for Enzyme Immobilization
por: Li, Jian, et al.
Publicado: (2015)